William Vega Ocasio, MD
Nephrology · Cayey, PRNPI 1598750317
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,930 of the $40,245 with a category attached, or 91.8%. Boehringer Ingelheim accounts for 71.7% of it on its own, with 12 other manufacturers making up the rest. Among nephrology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $619.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$29K
- Lilly USA, LLC$11K
- Amgen$125
- AstraZeneca$123
- Aurinia Pharma U.S., Inc.$123
- Sanofi-aventis U.S. LLC$90
- plus $226 from 7 others
What the payments were for
- Speaking & faculty fees$36,93092%
- Travel & lodging$9672%
- Food & beverage$2,1875%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 39 | $28,843 |
| Lilly USA, LLC | 10 | $10,715 |
| Amgen | 1 | $125 |
| AstraZeneca | 3 | $123 |
| Aurinia Pharma U.S., Inc. | 1 | $123 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Mallinckrodt Hospital Products Inc. | 1 | $62 |
| Fresenius USA Marketing, Inc. | 1 | $60 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Bayer Puerto Rico Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,245 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 826 | $536,639 |
| FarxigaDapagliflozin Propanediol | 665 | $416,638 |
| GlyxambiEmpagliflozin/Linagliptin | 399 | $258,241 |
| TrulicityDulaglutide | 138 | $139,198 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 211 | $129,021 |
| TradjentaLinagliptin | 139 | $79,980 |
| Xigduo XrDapaglifloz Propaned/Metformin | 90 | $54,660 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 87 | $52,433 |
| Omega-3 Acid Ethyl Esters | 618 | $35,344 |
| Sevelamer Carbonate | 309 | $31,848 |
| EliquisApixaban | 41 | $29,364 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $28,470 |
| SynjardyEmpagliflozin/Metformin Hcl | 41 | $27,988 |
| KerendiaFinerenone | 40 | $26,637 |
| JanuviaSitagliptin Phosphate | 40 | $26,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta, Synjardy Xr | $28,843 | $1,084,3021,703 claims |
| AstraZenecaFarxiga, Brilinta | $123 | $425,786681 claims |
| Lilly USA, LLCTrulicity, Humalog, Humalog Mix 75-25, Humulin 70-30, Humulin N | $10,715 | $171,323427 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $90 | $37,570125 claims |
| Johnson & JohnsonXarelto | $19 | $9,97216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Cayey
- Josue CastresanaCayey$8K
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
- Stephanie Colon-LopezBayamon$13K
- Pedro ColtonSanturce$12K
- Rafael Burgos CalderonBayamon$12K
- Angel Rivera SantosPonce$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.